Adocia SA

Adocia SA

Adocia SA

Overview
Date Founded

2005

Headquarters

115 avenue Lacassagne, Lyon, 69003, FRA

Type of Company

Public

Employees (Worldwide)

125

Industries

Biotechnology
Commercial Scientific Research

Company Description

Adocia SA operates as a clinical-stage biotechnology company, which engages in the development of medicines from already approved therapeutic agents. Its product pipeline includes BioChaperone PDGF, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase I/II clinical trials, as well as in pre-clinical staged for the treatment of diabetes; and Driveln, which is in preclinical stage for the treatment of oncology. The company was founded by Gérard Soula, OLivier Soula, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.

Website
Executives & Employees

Co-Founder

Co-Founder

Co-Founder

Chief Medical Officer

Chief Financial Officer, Chief Administrative Officer & IR Contact

Scientific Director

Director-Human Resources Development Department

Director-Pharmaceutical Development

Subscribe now to see full list of current and former executives
Board of Directors

Co-Founder at Adocia SA

Secretary at Institut Mérieux SA

Co-Founder at Adocia SA

Deputy General Manager at BPIFrance Investissement SAS

Senior Investment Director at BPIFrance Investissement SAS

Partner at Capricorn Venture Partners NV

Subscribe now to see full list of current and former board members
Paths to Adocia SA
Potential Connections via
Relationship Science
You
Adocia SA
Owners & Shareholders
Details Hidden

Gestys SA is a French private company located in Paris that provides portfolio management services. It was founded in 2000. Alain d'Anglade is currently the CEO of the firm.

Details Hidden

Perinvest aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon.Perinvest's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Details Hidden

Iris Finance SA is a French private company located in Paris, with subsidiaries in Luxembourg. The firm provides Investment Advice. It was founded in 1994. Dominique Pouliquen is currently the CEO of the company.

Subscribe now to see full details
Recent Transactions
Details Hidden

Adocia SA issued Ordinary Shares

Subscribe now to see full list of recent transations
Transaction Advisors
Underwriter

Advised onAdocia SA issued Ordinary Shares

Lead Manager

Advised onAdocia SA issued Ordinary Shares

Subscribe now to see transaction advisors for over 2.5 million organizations
Subscribe now to see transaction advisors for over 2.5 million organizations
Clients

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Subscribe now to see clients for over 2.5 million organizations
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$105M
Total Enterprise Value
$367M
Earnings Per Share
$-1.2
Revenue
$22.5M
Net Profit
$-7.89M
EBITDA
$-15.2M
EBITDAMargin
-67.61%
Total Debt
$7.07M
Total Equity
$42.8M
Enterprise Value Sales
16.31x
TEVNet Income
-46.47x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
59.06%
Five Year Compounded Annual Growth Rate Of Revenue
70.71%
Subscribe now to see full financial details
Investors
Details Hidden

Co-Founder at Adocia SA

Details Hidden

Co-Founder at Adocia SA

Details Hidden

Co-Founder at Adocia SA

Subscribe now to see full details
Suppliers

Antoax A/S is a Danish private company with domestic subsidiaries, involved in investors,.

North American Science Associates, Inc. Commercial Scientific Research | Northwood, OH

North American Science Associates, Inc. operates as a medical research organization that provides expert regulatory, laboratory, clinical, and compliance services to medical device and healthcare product manufacturers. Its services include consulting, testing, clinical, medical device testing, therapeutic expertise, and sterilization products. The company was founded by Theodore Gorski and Lucille F. Gorski in 1967 and is headquartered in Northwood, OH.

Subscribe now to see suppliers for over 2.5 million organizations
Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, New Jersey

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Biocon Ltd. Pharmaceuticals - Bangalore, KA

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Sanofi Pharmaceuticals - Paris, IF

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health